Evidence map›Paper›PMID 41567638›Full record

ArticleFrontiers in pharmacology2025

Synergistic therapy for diabetic retinopathy via dual blockade of VEGF-A and TNF-α with a bispecific nanobody.

Chenlu Wu, Yue Shen, Chengnan Xu, Chong Bi, Chenyue Yan, Jinping Niu, Wenyun Zheng, Xingyuan Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chenlu WuSchool of Biotechnology and State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Yue ShenSchool of Biotechnology and State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Chengnan XuSchool of Pharmacy, Shanghai Key Laboratory of New Drug Design, East China University of Science and Technology, Shanghai, China.
Chong BiSchool of Pharmacy, Shanghai Key Laboratory of New Drug Design, East China University of Science and Technology, Shanghai, China.
Chenyue YanSchool of Pharmacy, Shanghai Key Laboratory of New Drug Design, East China University of Science and Technology, Shanghai, China.
Jinping NiuSchool of Biotechnology and State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Wenyun ZhengSchool of Pharmacy, Shanghai Key Laboratory of New Drug Design, East China University of Science and Technology, Shanghai, China.
Xingyuan MaSchool of Biotechnology and State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Anti-vascular endothelial growth factor (VEGF) therapy fails in approximately 30% of diabetic retinopathy (DR) patients, indicating the limitations of solely targeting VEGF-A. This study aimed to design a bispecific nanobody, Nb-TV, targeting both tumor necrosis factor-α (TNF-α) and VEGF-A to achieve dual anti-inflammatory and anti-angiogenic effects for potential DR treatment. Methods: The inhibitory effects of Nb-TV were evaluated Results: Discussion: Our findings demonstrate that Nb-TV mechanistically dual-targets the TNF-α/NF-κB and VEGF-A/MAPK pathways, mitigating both inflammation and angiogenesis synergistically. This validates Nb-TV as a novel bispecific nanobody with promising therapeutic potential for DR by simultaneously modulating key pathological pathways. This study not only proposes a strategic approach for refractory DR but also provides a framework for targeting other multifactorial ocular and systemic diseases.

Indexed as

bispecific nanobodydiabetic retinopathydual-targetingTNF-αVEGF-A

Identifiers

PMID41567638
PMCPMC12816300

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.